Eyevance Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for EYEVANCE, and what generic alternatives to EYEVANCE drugs are available?
EYEVANCE has seven approved drugs.
There are seven US patents protecting EYEVANCE drugs.
There are twenty-two patent family members on EYEVANCE drugs in seven countries and five supplementary protection certificates in four countries.
Drugs and US Patents for Eyevance
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eyevance | TOBRADEX ST | dexamethasone; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050818-001 | Feb 13, 2009 | RX | Yes | Yes | 7,795,316 | See Plans and Pricing | Y | See Plans and Pricing | |||
Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 9,254,286*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
Eyevance | NATACYN | natamycin | SUSPENSION;OPHTHALMIC | 050514-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 8,829,005*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eyevance
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eyevance | TOBRADEX ST | dexamethasone; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050818-001 | Feb 13, 2009 | 5,149,694 | See Plans and Pricing |
Eyevance | VEXOL | rimexolone | SUSPENSION/DROPS;OPHTHALMIC | 020474-001 | Dec 30, 1994 | 4,686,214 | See Plans and Pricing |
Eyevance | TOBRASONE | fluorometholone acetate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050628-001 | Jul 21, 1989 | 5,149,693 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Eyevance Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2021138760 | See Plans and Pricing |
Japan | 2018141022 | See Plans and Pricing |
Japan | 6033677 | See Plans and Pricing |
Japan | 2016190878 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eyevance Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1429780 | SPC/GB12/058 | United Kingdom | See Plans and Pricing | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
1429780 | 13C0012 | France | See Plans and Pricing | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
0058146 | 2001C/045 | Belgium | See Plans and Pricing | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
1581193 | SPC/GB12/047 | United Kingdom | See Plans and Pricing | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.